Skip to main content

Table 4 Health state utility values derived from the two-part model

From: EQ-5D-3L health state utility values in transfusion-dependent thalassemia patients in Malaysia: a cross-sectional assessment

Health state Full sample (n = 585) Restricted sample (n = 429)
Utility value 95% CI Utility value 95% CI
TDT with non-specific iron overload complication 0.852 0.811 0.893 0.905 0.880 0.929
TDT with cardiac complication 0.820 0.742 0.897 0.846 0.805 0.887
TDT with diabetes 0.815 0.711 0.919 0.839 0.788 0.890
TDT with hypothyroid 0.853 0.761 0.945 0.838 0.787 0.889
TDT with hypogonadism 0.841 0.785 0.896 0.860 0.827 0.893
TDT with hypoparathyroidism 0.894 0.832 0.955 0.856 0.815 0.897
TDT with liver iron overload 0.826 0.778 0.875 0.929 0.907 0.951
TDT with desferrioxamine (DFO) 0.893 0.880 0.906 0.779 0.707 0.852
TDT with deferasirox (DFX) 0.915 0.856 0.974 0.854 0.837 0.870
TDT with deferiprone (DFP) 0.940 0.875 1.005 0.778 0.698 0.859
TDT with DFO + DFP 0.903 0.841 0.964 0.749 0.691 0.808
TDT with DFO + DFX 0.862 0.229 0.953 0.758 0.662 0.854
TDT with DFX + DFP 0.814 0.653 0.975 0.754 0.591 0.917
TDT on subcutaneous (SC) therapy 0.893 0.879 0.906 0.779 0.706 0.852
TDT on oral (PO) therapy 0.918 0.860 0.976 0.949 0.902 0.997
TDT on SC + PO therapy 0.895 0.834 0.957 0.890 0.837 0.942
  1. CI, confidence interval; TDT, transfusion-dependent thalassemia; DFO, desferrioxamine; DFX, deferasirox; DFP, deferiprone; SC, subcutaneous; PO, oral